|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HYPK |
Gene summary for HYPK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HYPK | Gene ID | 25764 |
| Gene name | huntingtin interacting protein K | |
| Gene Alias | C15orf63 | |
| Cytomap | 15q15.3 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | Q9NX55 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25764 | HYPK | LZE4T | Human | Esophagus | ESCC | 6.19e-10 | 2.66e-01 | 0.0811 |
| 25764 | HYPK | LZE5T | Human | Esophagus | ESCC | 1.57e-03 | 3.57e-01 | 0.0514 |
| 25764 | HYPK | LZE20T | Human | Esophagus | ESCC | 4.98e-02 | 1.37e-01 | 0.0662 |
| 25764 | HYPK | LZE22T | Human | Esophagus | ESCC | 1.48e-05 | 5.80e-01 | 0.068 |
| 25764 | HYPK | LZE24T | Human | Esophagus | ESCC | 7.65e-05 | 1.30e-01 | 0.0596 |
| 25764 | HYPK | LZE21T | Human | Esophagus | ESCC | 6.52e-03 | 2.25e-01 | 0.0655 |
| 25764 | HYPK | P1T-E | Human | Esophagus | ESCC | 1.05e-17 | 5.80e-01 | 0.0875 |
| 25764 | HYPK | P2T-E | Human | Esophagus | ESCC | 9.44e-07 | 1.61e-01 | 0.1177 |
| 25764 | HYPK | P4T-E | Human | Esophagus | ESCC | 4.30e-23 | 5.80e-01 | 0.1323 |
| 25764 | HYPK | P5T-E | Human | Esophagus | ESCC | 2.13e-15 | 4.25e-01 | 0.1327 |
| 25764 | HYPK | P8T-E | Human | Esophagus | ESCC | 1.39e-13 | 2.50e-01 | 0.0889 |
| 25764 | HYPK | P9T-E | Human | Esophagus | ESCC | 8.16e-12 | 2.85e-01 | 0.1131 |
| 25764 | HYPK | P10T-E | Human | Esophagus | ESCC | 2.51e-08 | 1.65e-01 | 0.116 |
| 25764 | HYPK | P11T-E | Human | Esophagus | ESCC | 1.13e-06 | 2.75e-01 | 0.1426 |
| 25764 | HYPK | P12T-E | Human | Esophagus | ESCC | 4.80e-13 | 3.09e-01 | 0.1122 |
| 25764 | HYPK | P16T-E | Human | Esophagus | ESCC | 2.34e-08 | 3.07e-01 | 0.1153 |
| 25764 | HYPK | P17T-E | Human | Esophagus | ESCC | 1.49e-02 | 1.52e-01 | 0.1278 |
| 25764 | HYPK | P19T-E | Human | Esophagus | ESCC | 5.57e-05 | 3.09e-01 | 0.1662 |
| 25764 | HYPK | P20T-E | Human | Esophagus | ESCC | 6.20e-06 | 1.54e-01 | 0.1124 |
| 25764 | HYPK | P21T-E | Human | Esophagus | ESCC | 1.18e-08 | 1.39e-01 | 0.1617 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
| GO:0050821111 | Esophagus | ESCC | protein stabilization | 140/8552 | 191/18723 | 6.50e-15 | 3.61e-13 | 140 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HYPK | SNV | Missense_Mutation | novel | c.270C>G | p.Ile90Met | p.I90M | Q9NX55 | protein_coding | deleterious(0) | possibly_damaging(0.804) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| HYPK | SNV | Missense_Mutation | c.251A>T | p.Glu84Val | p.E84V | Q9NX55 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HYPK | SNV | Missense_Mutation | rs372106020 | c.368N>T | p.Ala123Val | p.A123V | Q9NX55 | protein_coding | deleterious(0) | benign(0.046) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HYPK | SNV | Missense_Mutation | c.74G>C | p.Gly25Ala | p.G25A | Q9NX55 | protein_coding | tolerated(0.59) | benign(0.373) | TCGA-AX-A06B-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HYPK | SNV | Missense_Mutation | rs372106020 | c.368N>T | p.Ala123Val | p.A123V | Q9NX55 | protein_coding | deleterious(0) | benign(0.046) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HYPK | SNV | Missense_Mutation | novel | c.169N>G | p.Ser57Gly | p.S57G | Q9NX55 | protein_coding | tolerated(0.11) | possibly_damaging(0.64) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HYPK | SNV | Missense_Mutation | rs781154272 | c.331N>T | p.Arg111Cys | p.R111C | Q9NX55 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B5-A5OD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD |
| HYPK | SNV | Missense_Mutation | novel | c.191T>C | p.Met64Thr | p.M64T | Q9NX55 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HYPK | SNV | Missense_Mutation | novel | c.53N>T | p.Glu18Val | p.E18V | Q9NX55 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-CN-6020-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| HYPK | SNV | Missense_Mutation | novel | c.290N>A | p.Leu97Gln | p.L97Q | Q9NX55 | protein_coding | deleterious(0) | probably_damaging(0.94) | TCGA-CQ-A4CD-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |